New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery

Sosnik, Alejandro; Carcaboso, Ángel M.; Glisoni, Romina Julieta; Morettón, Marcela A.; Chiappetta, Diego Andrés

doi:10.1016/j.addr.2009.11.023

Cited by 244 publications

(152 citation statements)

References 111 publications

Supporting

Mentioning

139

Contrasting

Unclassified

Order By: Relevance

“…These nanoparticulate drug delivery systems have been demonstrated to enhance in vivo drug performance, with improved plasma membrane permeability, tissue selectivity and even controlled drug release. [23] It is envisioned for the use of nanocarriers may improve TB treatment efficiency. Magnetic barcode assay.…”

Section: Nanomaterials In Tb Drug Deliverymentioning

confidence: 99%

Nanomaterials in the Prevention, Diagnosis, and Treatment of Mycobacterium Tuberculosis Infections

Liang

Ding

et al. 2017

Adv Healthcare Materials

View full text Add to dashboard Cite

worldwide was estimated at a staggering 10.4 million, with a significant percentage (10%) resulting from concomitant HIV-TB coinfections. [1] Given the closely knitted association between TB infections and poor sanitation/poverty, it thus comes with no surprise that an overwhelming majority of disease burden (60%) is actually shouldered by countries from the developing world (Figure 1). [1] TB infections are compounded by the emergence of multidrug resistance (MDR). In spite of the tremendous amount of resources and research dollars that have been devoted to TB research, TB diagnostics and treatment outcomes still remain startlingly poor. TB remains worryingly underreported, under-diagnosed and undertreated. A 4.3 million gap was reported between incident and notified TB cases, chiefly in developing countries; majority of TB infections remain latent and unreported, and only 30% of new incident TB cases were subjected to drug susceptibility testing. [1] The Xpert Mycobacterium Tuberculosis (MTB)/RIF assay remains the only available WHOrecommended rapid diagnostic platform for detection of TB and drug (rifampicin) resistance. Treatment success rates are highly variable, ranging from 28% (extensively drug-resistant strains) to 83% (garden strains) of TB. The rate of decline in TB incidence has remained stagnant at 1.5% annually over the past decade, far lagging behind the 5% projected by the WHO's End TB Strategy. Against such a backdrop, TB remains firmly entrenched among the top 10 causes of death worldwide. [2] To this end, the WHO has since 2015, adopted the End TB Strategy in an effort to stem this burgeoning epidemic. Major diagnostic and treatment gaps in TB management still remain, and these need to be addressed to effectively curtail TB spread and its impact on global health. Pathogenesis of TB InfectionsMTB is the infectious agent responsible for TB infections. It originates from the family Mycobacteriaceae and is an obligate bacteria chiefly spread via air droplets.

show abstract

Section: Nanomaterials In Tb Drug Deliverymentioning

confidence: 99%

Nanomaterials in the Prevention, Diagnosis, and Treatment of Mycobacterium Tuberculosis Infections

Liang

Ding

et al. 2017

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…Niosomes proved to be effective and better drug delivery systems than liposomes 13 in case of sterilisation, high production costs, scale-up difficulties and the instability of phospholipidic components due to light exposure even at room temperature. Niosomes hold hydrophilic drugs within core and lipophilic ones by entrapment in hydrophobic domains (Sosnik et al, 2010). In a study, Jain and Vyas generated RIF loaded niosomes of micro size, 8-15 µm along with Span 85 as surfactant (Jain et al, 1995).…”

Section: Recently Wang Et Al Developed Poly-(ethylene Glycol) Modifmentioning

confidence: 99%

“…PEO-PPO [poly-(ethylene oxide)-poly-(propylene oxide)] block copolymers (linear poloxamers and branched poloxamines) are some of the significant commercially available micelle forming materials approved by Food and Drug Administration (Chiappetta et al, 2007). Polymeric micelles are more stable than the conventional micelles even at concentration below CMC (Sosnik et al, 2010). Zahroor et al used ionotropic gelation method for preparing alginate NPs (235 nm) loaded with anti-TB drugs.…”

Section: Figmentioning

confidence: 99%

“…Dendrimers are macromolecules displaying structural perfection; these are regularly hyperbranched, 3-dimensional, relatively low molecular weight, polydispersity and adjustable functionality (Sosnik et al, 2010 Liposomes are composite structures of nano to micro sizes consisting of a phospholipid bilayer that surrounds an aqueous core (Gregoriadis et al, 1974). Liposome's core can encapsulate water soluble drugs while the hydrophobic domain can entrap the insoluble agents (Sosnik et al, 2010), Fig.…”

Section: Figmentioning

confidence: 99%

“…Liposome's core can encapsulate water soluble drugs while the hydrophobic domain can entrap the insoluble agents (Sosnik et al, 2010), Fig. 3.…”

Section: Figmentioning

confidence: 99%

See 2 more Smart Citations

Interaction of Nanoparticles in Biological Systems and their Role in Therapeutical Treatment of Tuberculosis and Cancer

Meena¹,

Singh²,

Sahare³

et al. 2014

JLA

View full text Add to dashboard Cite

The kind of interactions which nanoparticles show in the biological systems is very interesting. Nanoparticles (NPs) on entering the living system immediately come in contact with proteins which serve many applications of nanoparticles including bio-signalling, therapeutics and drug delivery systems. Moreover, many inorganic oxide nanoparticles can also serve the purpose of antibacterial/antiviral by assisting in the production of reactive oxygen species (ROS). The role of nanoparticles in therapeutics is very significant and increasing day-by-day as it assures better treatment to the patient by enhancing activity of drug, improving bioavailability, flexibility in deciding route of administration and long term stability of drug resulting in better treatments of diseases. NPs such as solid lipid NPs, polymeric NPs, porous NPs, liposomes are being used for treatment of various types of diseases. Numerous carriers based drug delivery systems incorporating anti-TB drugs have been developed for target site actions. NPs encapsulating anti-cancer drugs such as doxorubicin, paclitaxel have also been developed for treatment of different types of cancers. Results of these studies give hopes to the researchers for the use of nanoparticles in the field of therapeutics. The NPs can be toxic as well as nontoxic to the biological system. Therefore, some adverse effects, such as, cytotoxicity on inhaling some kinds of nanoparticles must be kept in mind for judicious use of such systems during synthesis or during handling. The paper describes recent developments in the field by reviewing the available literature.

show abstract

Nanoparticles: Scope in Drug Delivery

Tanwar

Meena

2014

Advanced Biomaterials and Biodevices

View full text Add to dashboard Cite

New old challenges in tuberculosis: Potentially effective nanotechnologies in drug delivery

Cited by 244 publications

References 111 publications

Nanomaterials in the Prevention, Diagnosis, and Treatment of Mycobacterium Tuberculosis Infections

Nanomaterials in the Prevention, Diagnosis, and Treatment of Mycobacterium Tuberculosis Infections

Interaction of Nanoparticles in Biological Systems and their Role in Therapeutical Treatment of Tuberculosis and Cancer

Nanoparticles: Scope in Drug Delivery

Contact Info

Product

Resources

About